Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Mar;3(3):423-432.
doi: 10.3892/etm.2011.412. Epub 2011 Dec 8.

Prognostic factors in patients with pancreatic cancer

DE-Xiang Zhang  1 , Yue-DI Dai, Su-Xu Yuan, Li Tao
Affiliations

Prognostic factors in patients with pancreatic cancer

DE-Xiang Zhang et al. Exp Ther Med. 2012 Mar.

Abstract

The identification of prognostic factors for pancreatic cancer patients could provide insightful information for their management in the clinic. A total of 302 pancreatic cancer patients were enrolled in this study. The clinicopathological characteristics, treatment selection and laboratory test data were retrospectively retrieved from the medical records and follow-up data were obtained via telephone interview. Cox survival analysis was used to assess the potential prognostic factors, and survival curves were obtained by Kaplan-Meier analyses. The mortality rate of the patients was 83.4% (252/302) and the median survival of these patients was 6.1 months, with 1-, 2- and 3-year survival rates of 30.1 (91/302), 10.6 (32/302) and 2.6% (8/302), respectively. The most influential factors for the survival of these patients were the site of primary cancer, tumor stage, treatment selection, serum levels of glutamic-pyruvic transaminase, albumin, lactate dehydrogenase and hemoglobin, and white blood cell counts (P<0.05). The median survival of patients who did not receive any treatment or just received supportive treatment was 1.3 months, while the median overall survival of patients who underwent surgery, chemotherapy, biliary drainage therapy, arterial interventional chemotherapy and comprehensive treatment was 11.0, 7.3, 3.5, 9.0 and 11.0 months, respectively (P<0.05). Furthermore, single-drug chemotherapy was not statistically associated with patient survival in those who received the multi-drug regimen (P>0.05). However, the mortality risk of patients who received platinum chemotherapy was decreased [hazard ratio (HR)=0.56, 95% CI 0.35-0.88, P=0.011] compared to the patients who did not receive this treatment (P<0.05). Tumor stage, treatment selection, serum albumin levels, urea nitrogen, CA19-9, white blood cell and platelet counts were independent prognostic factors for the prediction of survival in pancreatic cancer. Future studies are required in order to verify these data. Chemotherapy with platinum regimens could improve overall survival in patients with pancreatic cancer.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.
Overall survival and association of the primary tumor locations and tumor stage with overall survival of 302 pancreatic cancer patients analyzed using the Kaplan-Meier method.
Figure 2.
Figure 2.
Comparison of the effect of treatment selections on overall survival.
Figure 3.
Figure 3.
Comparison of the effect of liver functions on overall survival.
Figure 4.
Figure 4.
Comparison of the effects of lactate dehydrogenase, albumin and glucose levels on overall survival.
Figure 5.
Figure 5.
Comparison of the effects of white blood cell count and hemoglobin levels and platelet count on overall survival.
Figure 6.
Figure 6.
Comparison of the effect of kidney functions on overall survival.
Figure 7.
Figure 7.
Comparison of the effects of various tumor markers on overall survival.
See this image and copyright information in PMC

References

    1. Goldstein D, Carroll S, Apte M, et al. Modern management of pancreatic carcinoma. Intern Med J. 2004;34:475–481. - PubMed
    1. Hirata K, Sato T, Mukaiya M, et al. Results of 1001 resections for invasive ductal adenocarcinoma of the pancreas. Arch Surg. 1997;132:771–776. - PubMed
    1. Nakao A, Harada A, Nonami T, et al. Lymph node metastasis in carcinoma of the body and tail of the pancreas. Br J Surg. 1997;84:1090–1092. - PubMed
    1. Shimada K, Sakamoto Y, Sano T, et al. Prognostic factors after distal pancreatectomy with extended lymphadenectomy for invasive pancreatic adenocarcinoma of the body and tail. Surgery. 2006;139:288–295. - PubMed
    1. Neoptolemos JP, Stocken DD, Friess H, et al. A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004;350:1200–1210. - PubMed

LinkOut - more resources